Table 3.
Estimates for base case scenario
| Median PFS/TTP (months) | % of patients with grade 3 or 4 toxicity | Results of toxicity | Source | |||
|---|---|---|---|---|---|---|
| Dose reduction or delay | Treatment-related death | Discontinuation of therapy | ||||
| 1st Line | ||||||
| 5FU/LV (Mayo) | 4.7 | 43%* | 35% | 1% | 7% | 37 |
| FOLFOX | 8.7 | 81% | 63.2% | 2% | 16%* | Sargent, 2005, unpublished data |
| FOLFIRI | 8.5 | 53% | 43%* | 4%** | 6% | 18 |
| FOLFOX and Bevacizumab | 13.1 | 81% | 63.2 | 2% | 16%* | |
| FOLFIRI and Bevacizumab | 12.9 | 53% | 43%* | 4%** | 6% | |
| 2nd/3rd Line | ||||||
| Irinotecan | 4.2 | 69% | 59% | 0 | 10% | 38 |
| FOLFOX | 4.6 | 36% | 26% | 2% | 8% | 39 |
| Cetuximab | 1.5 | 43.5% | 42.3% | 0 | 1.2% | 5 |
| Cetuximab and Irinotecan | 4.1 | 61.5% | 61.5% | 0 | 1.2% | 5 |
*
calculated from available data.